Evidence map›Paper›PMID 25874698›Full record

Observational studyPloS one2015

Frequency and characteristics of familial melanoma in Spain: the FAM-GEM-1 Study.

Iván Márquez-Rodas, Manuel Martín González, Eduardo Nagore, Cristina Gómez-Fernández, Jose Antonio Avilés-Izquierdo, Cayetana Maldonado-Seral, Virtudes Soriano, Margarita Majem-Tarruella, Virginia Palomar, Rocio Maseda and 16 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Dendritic cell therapy in melanoma.Annals of translational medicine · 2017
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 20 institutions in 2 countries.

Iván Márquez-RodasServicio de Oncología Médica, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
Manuel Martín GonzálezServicio de Dermatología, Hospital Ramón y Cajal, Madrid, Spain.
Eduardo NagoreServicio de Dermatología, Instituto Valenciano de Oncología, Valencia, Spain.
Cristina Gómez-FernándezServicio de Dermatología, Hospital La Paz, Madrid, Spain.
Jose Antonio Avilés-IzquierdoServicio de Dermatología, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
Cayetana Maldonado-SeralServicio de Deramtología, Hospital Universitario Central de Asturias, Oviedo, Spain.
Virtudes SorianoServicio de Oncología Médica, Instituto Valenciano de Oncología, Valencia, Spain.
Margarita Majem-TarruellaServicio de Oncología Médcica, Hospital de Sant Pau, Barcelona, Spain.
Virginia PalomarServicio de Oncología Médica, Hospital General de Valencia, Valencia, Spain.
Rocio MasedaServicio de Dermatología, Hospital La Paz, Madrid, Spain.
Alfonso Martín-CarniceroServicio de Oncología Médica, Hospital de San Pedro, Logroño, Spain.
Teresa PuertolasServicio de Oncología, Hospital Universitario Miguel Servet, Zaragoza, Spain.
Elena GodoyServicio de Dermatología, Hospital de Cabueñes, Gijon, Spain.
Pablo CerezuelaServicio de Oncología Médica, Hospital General Universitario Santa Lucia, Cartagena, Spain.
Maria Ochoa de OlzaServicio de Oncología Médica, Instituto Catalan de Oncología, Hospitalet, Spain.
Begoña CamposServicio de Oncología Médica, Hospital Lucus Augusti, Lugo, Spain.
Elisabeth Perez-RuizServicio de Oncología Médica, Hospital Costa del Sol, Marbella, Spain.
Ainara SoriaServicio de Oncología Médica, Hospital Ramón y Cajal, Madrid, Spain.
Irene Gil-ArnaizServicio de Oncología Medica, Hospital Reina Sofía, Tudela, Spain.
Maria Gonzalez-CaoServico de Oncología Médica, Instituto Dexeus, Barcelona, Spain.
Elisa GalvezServicio de Oncología Médica, Hospital de Elda, Alicante, Spain.
Ana AranceServicio de Oncología Medica, Hospital Clinic, Barcelona, Spain.
Joaquin BelonServicio de Oncología Médica, Clínica Oncogranada, Granada, Spain.
Luis de la Cruz-MerinoServicio de Oncología Médica, Hospital Virgen de la Macarena, Sevilla, Spain.
Salvador Martín-AlgarraDepartamento de Oncología, Clínica Universidad de Navarra, Pamplona, Spain.
Spanish Multidisciplinary Group of Melanoma (GEM)
Fundación Instituto Valenciano de Oncología · ESHospital General Universitario Gregorio Marañón · ESHospital Universitario La Paz · ESHospital Universitario Ramón y Cajal · ESClinica Universidad de Navarra · ESHospital Clínic de Barcelona · ESHospital Costa del Sol · ESHospital de Sant Pau · ESHospital General de Elda · ESHospital General Universitario De Valencia · ESHospital San Pedro · ESHospital Universitario Central de Asturias · ESHospital Universitario De Cabueñes · ESHospital Universitario Dexeus · ESHospital Universitario Lucus Augusti · ESHospital Universitario Miguel Servet · ESHospital Universitario Reina Sofía · ESHospital Universitario Virgen Macarena · ESInstitut Català d'Oncologia · ESSanta Lucía University General Hospital · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionFamilial history of melanoma is a well-known risk factor for the disease, and 7% melanoma patients were reported to have a family history of melanoma. Data relating to the frequency and clinical and pathological characteristics of both familial and non-familial melanoma in Spain have been published, but these only include patients from specific areas of Spain and do not represent the data for the whole of Spain. PATIENTS AND

methodsAn observational study conducted by the Spanish Group of Melanoma (GEM) analyzed the family history of patients diagnosed with melanoma between 2011 and 2013 in the dermatology and oncology departments.

resultsIn all, 1047 patients were analyzed, and 69 (6.6%) fulfilled criteria for classical familial melanoma (two or more first-degree relatives diagnosed with melanoma). Taking into account other risk factors for familial melanoma, such as multiple melanoma, pancreatic cancer in the family or second-degree relatives with melanoma, the number of patients fulfilling the criteria increased to 165 (15.8%). Using a univariate analysis, we determined that a Breslow index of less than 1 mm, negative mitosis, multiple melanoma, and a history of sunburns in childhood were more frequent in familial melanoma patients, but a multivariate analysis revealed no differences in any pathological or clinical factor between the two groups.

conclusionsSimilar to that observed in other countries, familial melanoma accounts for 6.6% of melanoma diagnoses in Spain. Although no differences in the multivariate analysis were found, some better prognosis factors, such as Breslow index, seem more frequent in familial melanoma, which reflect a better early detection marker and/or a different biological behavior.

Indexed as

Genetic Predisposition to DiseaseCutaneous Malignant MelanomaFemaleHumansIncidenceMaleMelanomaMiddle AgedMultivariate AnalysisRisk FactorsSkin NeoplasmsSpain

Identifiers

PMID25874698
PMCPMC4395344
OpenAlexW2087175390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.